Background: A disposable set for platelet concentrate (PC) preparation by the buffy coat method allows pooling of buffy coats, centrifugation and cell separation with in-line leucocyte filtration. This study compares three commercially available pooling sets in combination with INTERCEPT pathogen inactivation (PI). Materials and methods: Sets for pooling of buffy coats were from Fresenius Kabi (FRE), Macopharma (MAC) and Terumo BCT (TER). Platelet yield, recovery and concentration were compared before and after PI (n = 20). Platelet quality was assessed by annexin V binding, P-selectin expression and PAC1 binding. Results: The TER pooling set had the highest platelet yield (539 044 x 10(11)) compared with MAC (453 +/- 077) and FRE (456 +/...
BACKGROUND: The Mirasol pathogen reduction technology (PRT) system uses riboflavin and ultraviolet...
BACKGROUND: The different production methods for platelet concentrates (PCs) result in products with...
BackgroundPlatelet (PLT) concentrates (PC) can be produced via the buffy coat (BC) or platelet-rich ...
Background: A disposable set for platelet concentrate (PC) preparation by the buffy coat method allo...
BACKGROUND: Buffy coat pooled platelet concentrate (BCPP) is a new blood component mainly used in Eu...
Background/Case Studies: In the past decade, technology for inactivation of potential pathogens and ...
Background/Case Studies: Basically, the automatic techniques OrbiSac® (Caridian BCT) and TACSI® ...
Background: Platelet rich plasma-platelet concentrate (PRP-PC), buffy coat poor-platelet concentrat...
BACKGROUND: Posttransfusion complications can be prevented by pretransfusion removal of donor white ...
Background: Pathogen inactivation methods for platelet concentrates are increasingly being used in b...
Background: Stored platelet concentrates (PC) are in increasing demand for transfusion to patients w...
BACKGROUND: Platelet concentrates (PCs) treated by the pathogen inactivation technology (PI) using ...
Background/Case Studies: New platelet additive solutions (PAS) containcompounds that might improve t...
Background: A photochemical treatment (PCT) process for inactivation of infectious pathogens and leu...
IntroductionIn the last decade, platelet-rich concentrates, including the so-called platelet-rich pl...
BACKGROUND: The Mirasol pathogen reduction technology (PRT) system uses riboflavin and ultraviolet...
BACKGROUND: The different production methods for platelet concentrates (PCs) result in products with...
BackgroundPlatelet (PLT) concentrates (PC) can be produced via the buffy coat (BC) or platelet-rich ...
Background: A disposable set for platelet concentrate (PC) preparation by the buffy coat method allo...
BACKGROUND: Buffy coat pooled platelet concentrate (BCPP) is a new blood component mainly used in Eu...
Background/Case Studies: In the past decade, technology for inactivation of potential pathogens and ...
Background/Case Studies: Basically, the automatic techniques OrbiSac® (Caridian BCT) and TACSI® ...
Background: Platelet rich plasma-platelet concentrate (PRP-PC), buffy coat poor-platelet concentrat...
BACKGROUND: Posttransfusion complications can be prevented by pretransfusion removal of donor white ...
Background: Pathogen inactivation methods for platelet concentrates are increasingly being used in b...
Background: Stored platelet concentrates (PC) are in increasing demand for transfusion to patients w...
BACKGROUND: Platelet concentrates (PCs) treated by the pathogen inactivation technology (PI) using ...
Background/Case Studies: New platelet additive solutions (PAS) containcompounds that might improve t...
Background: A photochemical treatment (PCT) process for inactivation of infectious pathogens and leu...
IntroductionIn the last decade, platelet-rich concentrates, including the so-called platelet-rich pl...
BACKGROUND: The Mirasol pathogen reduction technology (PRT) system uses riboflavin and ultraviolet...
BACKGROUND: The different production methods for platelet concentrates (PCs) result in products with...
BackgroundPlatelet (PLT) concentrates (PC) can be produced via the buffy coat (BC) or platelet-rich ...